Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis: A protocol for systematic review

INTRODUCTION: Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly used in the treatment of cancer. Immunosuppressive therapy can control the cancer well and is suitable for the moderate to severe diseases. However, according to clinical observa...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Deting, Dong, Jianyong, Li, Honglin, Ma, Tao, Yu, Wenjun, Song, Lucheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
3400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004689/
https://www.ncbi.nlm.nih.gov/pubmed/32000374
http://dx.doi.org/10.1097/MD.0000000000018701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004689/
https://www.ncbi.nlm.nih.gov/pubmed/32000374
http://dx.doi.org/10.1097/MD.0000000000018701

Ejemplares similares